Anthrax Vaccine Market: By Product Type (Live Vaccine, and Sub Unit Vaccine), By Distribution Channel (Hospitals, Defense & Military Centers, and Others), and Geography. 

Purchase Option

$ 4400
$ 6600
$ 8900

Anthrax Vaccine Market size was valued at USD 32.6 million in 2023 and is projected to reach USD xx million growing at a 3.1% CAGR from 2024 to 2030. The anthrax vaccine market plays a crucial role in biodefense preparedness by offering protection against Bacillus anthracis, the bacterium causing anthrax. Anthrax can infect animals, particularly livestock Healthcare. As awareness of this risk grows, veterinarians and agricultural workers may require vaccination to protect themselves from accidental exposure. This could lead to increased demand in the veterinary sector. In addition, governments might invest in anthrax vaccines for broader public health preparedness, especially in regions with a higher risk of anthrax outbreaks due to environmental factors or the historical presence of the bacteria.

Moreover, the chilling possibility of anthrax being used as a bioweapon remains a significant concern. The infamous 2001 anthrax attacks in the US serve as a stark reminder, prompting governments around the world to prioritize biodefense preparedness, including stockpiling anthrax vaccines. As developing economies strengthen their public health and biodefense capabilities, the demand for anthrax vaccines is expected to rise in these regions, particularly in Asia Pacific. Also, continued government investment in biodefense programs, including vaccine research, development, and stockpiling, will be crucial for sustained market growth. However, the rigorous regulatory approval processes for vaccines can hinder the development and introduction of new anthrax vaccines.

Anthrax Vaccine Market Key Developments:

  • In August 2023, the Lagos State Government was supported by the Federal Government with 50,000 vials of anthrax vaccines. Such initiatives are likely to drive the anthrax vaccine market growth.
  • In July 2023, CYFENDUS, developed by Emergent BioSolutions Inc., got the approval from the U.S. FDA for post-exposure prophylaxis of disease in people between 18 years to 65 years identified with Bacillus anthracis infection. This vaccine is given in association with mandated antiviral drugs.
  • In October 2022, US Biomedical Advanced Research and Development Authority (BARDA), nominated ICON plc as a part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to perform an anthrax vaccine clinical trial. The Anthrax vaccine AV7909 is presently under clinical trial evaluation.

Global Anthrax Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.1%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Anthrax Vaccine Market Dynamics

Research and development in vaccine technology are paving the way for improved anthrax vaccines with superior efficacy and reduced side effects. These advancements could broaden the market by making vaccination more appealing to a wider population, potentially encompassing civilians beyond high-risk groups. In addition, growing public awareness of bioterrorism and biological threats fuels investment in biodefense measures, including anthrax vaccines. This heightened awareness stems from media coverage of bioterrorism threats and historical events like the anthrax attacks. Moreover, military personnel face a heightened risk of exposure to anthrax due to potential biological warfare scenarios. This necessitates continuous procurement of anthrax vaccines by armed forces globally. Furthermore, countries with established biodefense programs and strong militaries, like those in North America and Europe, are likely to continue driving demand for stockpiling and military use of anthrax vaccines.

Global Anthrax Vaccine Market Segmentation

By Vaccine Type
  • Live Vaccines
  • Cell free PA Vaccines
By End User
  • Hospitals
  • Clinics,
  • Vaccination Centers
  • Others
By Geography
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The Anthrax Vaccine Market is growing at a CAGR of 3.1% over the Forecast Period

The North American region leads the Anthrax Vaccine market.

Emergent BioSolutions , Elusys Therapeutics, Panacea Biotec, Zoetis, Bayer, Colorado Serum Company, Inc, Biogénesis Bago, Emergent BioSolutions, Porton Biopharma Ltd, Merial, Merck, Altimmune, Inc. PharmAthene US Corp, Agrovet, CAVAC, Centro Diagnóstico Veterinario, Ceva Sante Animale

Historic years considered for the market study are 2019 to 2022, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.
1. Executive summary
2. Global Anthrax Vaccines Market Introduction
2.1. Global Anthrax Vaccines Market – Taxonomy
2.2. Global Anthrax Vaccines Market –Definitions
2.2.1. By Product Type
2.2.2. By Distribution Channel
2.2.3. By Region
3. Global Anthrax Vaccines Market Dynamics
3.1. Macro Economic factors
3.2. Forecast factors
3.3. Market Dynamics
3.4. Insights
4. Global Anthrax Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 – 2030
4.1. Market Analysis, 2019 – 2024 and Forecast, 2024 – 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Anthrax Vaccines Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030
5.1. Live Vaccine 
5.1.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Sub Unit Vaccine
5.2.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Anthrax Vaccines Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030
6.1. Hospitals
6.1.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Defense and Military Centers
6.2.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Anthrax Vaccines Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030
7.1. North America
7.1.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. RoW
7.4.1. Market Analysis, 2019 – 2023 and Forecast, 2024 – 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Global Anthrax Vaccines Market - Opportunity Analysis Index, By Product Type, Distribution Channel, and Region, 2024 – 2030
8. North America Anthrax Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
8.1. Product Type Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Live Vaccine
8.1.2. Sub Unit Vaccine
8.2. Distribution Channel Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Hospitals
8.2.2. Defense and Military Centers
8.3. Country Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1.1. U.S.
8.3.1.2. Canada
8.4. North America Anthrax Vaccines Market - Opportunity Analysis Index, By Product Type, Distribution Channel,  and Country, 2024 – 2030
8.5. North America Anthrax Vaccines Market Dynamics – Trends
9. Europe Anthrax Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
9.1. Product Type Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Live Vaccine
9.1.2. Sub Unit Vaccine
9.2. Distribution Channel Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Hospitals
9.2.2. Defense and Military Centers
9.3. Country Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. France
9.3.3. UK
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Anthrax Vaccines Market - By Product Type, Distribution Channel,  and Country, 2024 – 2030
9.5. Europe Anthrax Vaccines Market Dynamics – Trends
10. Asia-Pacific Anthrax Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
10.1. Product Type Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Live Vaccine
10.1.2. Sub Unit Vaccine
10.2. Distribution Channel Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Hospitals
10.2.2. Defense and Military Centers
10.3. Country Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. China
10.3.2. Japan
10.3.3. Australia & New Zealand
10.3.4. Rest of Asia-Pacific
10.4. Asia-Pacific Anthrax Vaccines Market - Opportunity Analysis Index, By Product Type, Distribution Channel,  and Country, 2024 – 2030
10.5. Asia-Pacific Anthrax Vaccines Market Dynamics – Trends
11. RoW Anthrax Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
11.1. Product Type Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Live Vaccine
11.1.2. Sub Unit Vaccine
11.2. Distribution Channel Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Hospitals
11.2.2. Defense and Military Centers
11.3. Country Analysis (2019 – 2023) and Forecast (2024 – 2030) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. GCC Countries
11.3.3. Rest of Latin America
11.4. RoW Anthrax Vaccines Market - Opportunity Analysis Index, By Product Type, Distribution Channel,  and Country, 2024 – 2030
11.5. RoW Anthrax Vaccines Market Dynamics – Trends
11.6. MEA Anthrax Vaccines Market - Opportunity Analysis Index, Opportunity Analysis Index, By Product Type, Distribution Channel,  and Country, 2024 – 2030
11.7. MEA Anthrax Vaccines Market Dynamics – Trends
12. Competition Landscape 
12.1. Strategic Dashboard of Top Market Players
12.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis)
12.2.1. Bukit Muria Jaya
12.2.2. EMERGENT BIOSOLUTIONS INC. 
12.2.3. Altimmune 
12.2.4. Panacea Biotec Limited 
12.2.5. Porton Biopharma Limited 
13. Research Methodology
14. Key Assumptions and Acronyms
  • Emergent BioSolutions 
  • Elusys Therapeutics 
  • Porton Biopharma Limited 
  • Panacea Biotec
  • Zoetis
  • Bayer
  • Colorado Serum Company, Inc.
  • Biogénesis Bago
  • Emergent BioSolutions
  • Merial, Merck
  • Altimmune, Inc.
  • PharmAthene US Corp
  • Agrovet
  • CAVAC
  • Centro Diagnóstico Veterinario
  • Ceva Sante Animale.

Adjacent Markets